Cargando…

An ABC transporter as a potential target against SHH-Medulloblastoma: From Benchtop to Bedside

Detalles Bibliográficos
Autores principales:	Zhu, Jingwen, Miller, Joseph N., Schuetz, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457923/ https://www.ncbi.nlm.nih.gov/pubmed/36093294 http://dx.doi.org/10.18632/oncotarget.28272

Ejemplares similares

Stem Cells in Musculoskeletal Regeneration: From Benchtop to Bedside
por: Fan, Jiabing, et al.
Publicado: (2016)

The transcriptional landscape of Shh medulloblastoma
por: Skowron, Patryk, et al.
Publicado: (2021)

Evasion of cell senescence in SHH medulloblastoma
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2016)

From Benchtop to Bedside: A Review of Oncolytic Virotherapy
por: Choi, Audrey H., et al.
Publicado: (2016)

Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
por: Koilkonda, Rajeshwari D., et al.
Publicado: (2011)

The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
por: Ghasemi, David R., et al.
Publicado: (2022)

EPCT-17. DEVELOPING EYA PHOSPHATASE INHIBITORS WITH ON-TARGET EFFECTS IN SHH-MEDULLOBLASTOMA
por: H. Hwang, Grace, et al.
Publicado: (2021)

Disruption of rack1 suppresses SHH‐type medulloblastoma formation in mice
por: Liu, Fengjiao, et al.
Publicado: (2021)

Emerging microfluidics-enabled platforms for osteoarthritis management: from benchtop to bedside
por: Zou, Zhou, et al.
Publicado: (2022)

Nanobased Platforms for Diagnosis and Treatment of COVID-19: From Benchtop to Bedside
por: Bidram, Elham, et al.
Publicado: (2021)

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma
por: Remke, Marc, et al.
Publicado: (2013)

Principles of tumorigenesis and emerging molecular drivers of SHH‐activated medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Drug Delivery Systems for Hedgehog Inhibitors in the Treatment of SHH-Medulloblastoma
por: Caimano, Miriam, et al.
Publicado: (2021)

Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma
por: Lukoseviciute, Monika, et al.
Publicado: (2023)

Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas
por: Menyhárt, Otília, et al.
Publicado: (2019)

Involvement of long non-coding RNA in colorectal cancer: From benchtop to bedside (Review)
por: YE, LE-CHI, et al.
Publicado: (2015)

M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas
por: Lee, Chanhee, et al.
Publicado: (2018)

BIOL-08. IGFBP2 PROMOTES TUMOR METASTASIS IN SHH MEDULLOBLASTOMA
por: Kunhiraman, Haritha, et al.
Publicado: (2021)

EMBR-19. SHH-DRIVEN MEDULLOBLASTOMA WITH CONCURRENT UNILATERAL RENAL AGENESIS
por: Aaroe, Ashley, et al.
Publicado: (2021)

Protein arginine methyltransferase 5 regulates SHH-subgroup medulloblastoma progression
por: Wynn, Daniel T, et al.
Publicado: (2022)

The histone methyltransferase EZH2 as a druggable target in SHH medulloblastoma cancer stem cells
por: Miele, Evelina, et al.
Publicado: (2017)

Primary microcephaly gene CENPE is a novel biomarker and potential therapeutic target for non-WNT/non-SHH medulloblastoma
por: Fang, Huangyi, et al.
Publicado: (2023)

ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma
por: Ingram, Wendy J, et al.
Publicado: (2013)

Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma
por: Westphal, Maximillian S., et al.
Publicado: (2021)

Obstacles to Brain Tumor Therapy: Key ABC Transporters
por: Wijaya, Juwina, et al.
Publicado: (2017)

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma
por: Singh, Alok R., et al.
Publicado: (2016)

Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma
por: Łastowska, Maria, et al.
Publicado: (2019)

Pre- and Post-Zygotic TP53 De Novo Mutations in SHH-Medulloblastoma
por: Azzollini, Jacopo, et al.
Publicado: (2020)

Crosstalk between SHH and FGFR Signaling Pathways Controls Tissue Invasion in Medulloblastoma
por: Neve, Anuja, et al.
Publicado: (2019)

Recent advances in SHH medulloblastoma progression: tumor suppressor mechanisms and the tumor microenvironment
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2019)

EMBR-33. YAP1 FUNCTION IN SHH MEDULLOBLASTOMA PROGRESSION AND IMMUNE EVASION
por: Abdelfattah, Nourhan, et al.
Publicado: (2021)

MEDB-48. Infant medulloblastoma - SHH subtype – with residual disease. To treat or not to treat
por: Dahl, Christine, et al.
Publicado: (2022)

MEDB-66. Investigating intra-tumoral heterogeneity of extrachromosomal DNA in SHH medulloblastoma
por: Chapman, Owen, et al.
Publicado: (2022)

Sex differences in methylation profiles are apparent in medulloblastoma, particularly among SHH tumors
por: Moss, Rachel M., et al.
Publicado: (2023)

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality
por: Dang, Mai T., et al.
Publicado: (2021)

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality
por: Dang, Mai T., et al.
Publicado: (2023)

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
por: Zhang, Zhen-Yu, et al.
Publicado: (2014)

Role of ABC transporters in cancer chemotherapy
por: Sun, Yue-Li, et al.
Publicado: (2012)

From Bench to Bedside—Implementing the New ABC Approach for Atrial Fibrillation in an Emergency Department Setting
por: Gupta, Sophie, et al.
Publicado: (2022)

Correction: Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_o0ktt6sp8mfcutgugps17b94oh